Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network.
Aged
Aged, 80 and over
Blood Pressure
/ physiology
Cardiovascular Diseases
Cross-Sectional Studies
Diabetes Mellitus, Type 2
/ blood
England
Epidemiologic Research Design
Female
Glycated Hemoglobin
/ analysis
Humans
Hypoglycemic Agents
/ therapeutic use
Liraglutide
/ therapeutic use
Male
Middle Aged
Primary Health Care
cardiovascular disease
incretin therapy
liraglutide
primary care
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
05
12
2018
revised:
27
02
2019
accepted:
20
03
2019
pubmed:
23
3
2019
medline:
11
7
2020
entrez:
23
3
2019
Statut:
ppublish
Résumé
To explore the prevalence and describe the clinical characteristics of people with type 2 diabetes with a similar cardiovascular (CV) profile to that of the LEADER trial participants in a primary care setting in England. In this cross-sectional analysis, using the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network database, we identified people with type 2 diabetes meeting the LEADER inclusion criteria. We identified people's CV risk factors using computerized medical records. Additionally, we assessed the prescription pattern of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in this cohort. Of 1 275 461 adults, we identified 84 394 with type 2 diabetes, of whom 14 000 (16.6%) met the LEADER inclusion criteria for established or high-risk CV disease (RCGP RSC-CVD group). The LEADER cohort was younger than the RCGP RSC-CVD group (64.2 vs 73.2 years), had higher mean glycated haemoglobin (71.6 vs 67.1 mmol/mol) and blood pressure (BP) values (systolic BP: 135.9 vs 132.9 mmHg; diastolic BP: 77.2 vs 72.7 mmHg), and a higher mean body mass index (32.5 vs 30.9 kg/m In a cohort of English general practice patients, one in six people with type 2 diabetes met the LEADER inclusion criteria, and less than one in 10 of these received liraglutide, a drug which has demonstrated CV benefits amongst others. There is scope to improve the outlook in people with type 2 diabetes and high CV risk through evidence-based use of specific GLP-1RAs.
Identifiants
pubmed: 30900349
doi: 10.1111/dom.13710
pmc: PMC6619442
doi:
Substances chimiques
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Liraglutide
839I73S42A
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1661-1667Informations de copyright
© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
J Innov Health Inform. 2015 Nov 04;22(3):368-73
pubmed: 26577427
Diabetes Care. 2018 Dec;41(12):2669-2701
pubmed: 30291106
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Diabetes Ther. 2017 Apr;8(2):365-376
pubmed: 28324484
JAMA. 2015 Aug 18;314(7):687-99
pubmed: 26284720
Stud Health Technol Inform. 2018;247:161-165
pubmed: 29677943
Diabet Med. 2019 Jun;36(6):718-725
pubmed: 30246473
Br J Gen Pract. 2017 Oct;67(663):440-441
pubmed: 28963401
J Innov Health Inform. 2016 Dec 20;23(3):627-632
pubmed: 28059698
Diabetes Obes Metab. 2019 Jul;21(7):1661-1667
pubmed: 30900349
Lancet. 2017 Apr 8;389(10077):1399-1409
pubmed: 28237263
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
N Engl J Med. 2015 Dec 3;373(23):2247-57
pubmed: 26630143
N Engl J Med. 2017 Sep 28;377(13):1228-1239
pubmed: 28910237
N Engl J Med. 2013 Oct 3;369(14):1327-35
pubmed: 23992602
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Diabetes Ther. 2018 Jun;9(3):1397-1402
pubmed: 29605893
Lancet. 2018 Oct 27;392(10157):1519-1529
pubmed: 30291013
N Engl J Med. 2015 Jul 2;373(1):11-22
pubmed: 26132939
BMJ Open. 2016 Nov 24;6(11):e012801
pubmed: 27884846
Inform Prim Care. 2005;13(1):65-70
pubmed: 15949178
Diabetes. 2014 Dec;63(12):4186-96
pubmed: 25071023
Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886
pubmed: 28917545
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
N Engl J Med. 2013 Oct 3;369(14):1317-26
pubmed: 23992601
Eur J Prev Cardiol. 2017 Oct;24(15):1637-1645
pubmed: 28870145
N Engl J Med. 2012 Jul 26;367(4):319-28
pubmed: 22686416
BMJ Open. 2016 Apr 20;6(4):e011092
pubmed: 27098827
N Engl J Med. 2007 Jun 14;356(24):2457-71
pubmed: 17517853
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
N Engl J Med. 2017 Aug 24;377(8):723-732
pubmed: 28605603
N Engl J Med. 2015 Jul 16;373(3):232-42
pubmed: 26052984
Am Heart J. 2013 Nov;166(5):823-30.e5
pubmed: 24176437
Diabetes Care. 2018 Jan;41(Suppl 1):S73-S85
pubmed: 29222379